» Articles » PMID: 2460401

Spleen Lymphocyte Populations and Expression of Activation Markers in Rats Treated with the Potent New Immunosuppressive Agent FK-506

Overview
Journal Immunology
Date 1988 Sep 1
PMID 2460401
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Rats were immunized systemically with sheep red blood cells (SRBC) and treated with either FK-506 (1 mg/kg/day) or cyclosporin A (CsA) (25 mg/kg/day) for 7 days. Profound (greater than 90%) suppression of the production of splenic IgM-secreting plasma cells and circulating antibody levels was observed in animals receiving either drug. Immunosuppression was accompanied by significant increases in the incidence and absolute numbers of OX8+ (T-cytotoxic/suppressor) lymphocytes in the spleen, and there were corresponding reductions in the W3/25+:OX8 (CD4+:CD8+) ratio. The magnitude of these changes was not affected by drug combination. There were no significant alterations in B cells with either agent, whilst a small but significant increase in the incidence of macrophages was observed in all drug-treated groups. Neither FK-506 nor CsA affected IL-2 receptor (OX39) or MHC class II (OX6) antigen expression. This study demonstrates the remarkable immunosuppressive potency of FK-506 and its underlying capacity, like CsA, to affect regulatory T-lymphocyte subsets in vivo.

Citing Articles

Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation.

Peters D, Fitton A, Plosker G, Faulds D Drugs. 1993; 46(4):746-94.

PMID: 7506654 DOI: 10.2165/00003495-199346040-00009.


Inhibition of murine B-lymphocyte proliferation by the novel immunosuppressive drug FK-506.

Walliser P, Benzie C, Kay J Immunology. 1989; 68(3):434-5.

PMID: 2480331 PMC: 1385461.


Inhibition of T-lymphocyte activation by the immunosuppressive drug FK-506.

Kay J, Benzie C, Goodier M, Wick C, Doe S Immunology. 1989; 67(4):473-7.

PMID: 2475433 PMC: 1385316.


Influence of FK506 and cyclosporin A on alloantibody production and lymphocyte activation following blood transfusion.

Woo J, Propper D, MacLeod A, Thomson A Clin Exp Immunol. 1990; 82(3):462-8.

PMID: 1702375 PMC: 1535490. DOI: 10.1111/j.1365-2249.1990.tb05472.x.


The influence of FK-506 on the thymus: an immunophenotypic and structural analysis.

Ross C, Thomson A Immunology. 1990; 70(3):398-404.

PMID: 1696242 PMC: 1384172.


References
1.
Cunningham A, SZENBERG A . Further improvements in the plaque technique for detecting single antibody-forming cells. Immunology. 1968; 14(4):599-600. PMC: 1409394. View

2.
Kino T, Hatanaka H, Hashimoto M, Nishiyama M, Goto T, OKUHARA M . FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiot (Tokyo). 1987; 40(9):1249-55. DOI: 10.7164/antibiotics.40.1249. View

3.
Kino T, Hatanaka H, Miyata S, Inamura N, Nishiyama M, Yajima T . FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot (Tokyo). 1987; 40(9):1256-65. DOI: 10.7164/antibiotics.40.1256. View

4.
Ochiai T, Nakajima K, Nagata M, Suzuki T, Asano T, Uematsu T . Effect of a new immunosuppressive agent, FK 506, on heterotopic cardiac allotransplantation in the rat. Transplant Proc. 1987; 19(1 Pt 2):1284-6. View

5.
Ochiai T, Nakajima K, Nagata M, Hori S, Asano T, Isono K . Studies of the induction and maintenance of long-term graft acceptance by treatment with FK506 in heterotopic cardiac allotransplantation in rats. Transplantation. 1987; 44(6):734-8. DOI: 10.1097/00007890-198712000-00002. View